Retatrutide is an investigational medicine that has not yet received marketing authorisation from the Medicines and Healthcare products Regulatory Agency (MHRA) or the European Medicines Agency (EMA)
Concurrent use with an insulin secretagogue or insulin may raise the risk of hypoglycemia
Its also generally not recommended during pregnancy or breastfeeding, or for anyone with a history of pancreatitis, severe gastrointestinal disease, or a known allergy to tirzepatide or any of its components
Topline Ozempic and Mounjaro manufacturers are being sued over claims that the drugs cause gastroparesis, a severe stomach disorder, but some experts believe this assertion is inaccurate because the drugs only cause a temporary delay in stomach emptying
doi: 10.1530/eje.0.1320012 21 BonertVCarmichaelJWuZMirochaJPerezDAClarkeNJet al
PubMed CrossRef Idris I, Abdulla H, Tilbrook S, et al